Condition
Cytomegalovirus Infection Reactivation
Total Trials
2
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
1 treatments under study, led by Letermovir
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
Trial Status
Unknown1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (2)
Research Network
Common Treatments
- Letermovir1
Active Sponsors
- Merck Sharp & Dohme LLC1
- Jun Zhang1
- Anhui Provincial Hospital1
- National Natural Science Foundation of China1
Top Investigators
Xiamen University
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provicial Hospital)
Related Conditions
- Congenital Cytomegalovirus Infection1